Compare RVSN & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RVSN | BLRX |
|---|---|---|
| Founded | 2016 | 2003 |
| Country | Israel | Israel |
| Employees | 47 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.9M | 12.6M |
| IPO Year | N/A | 2010 |
| Metric | RVSN | BLRX |
|---|---|---|
| Price | $4.45 | $3.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | 18.1K | ★ 30.7K |
| Earning Date | 03-31-2026 | 05-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $860.32 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.17 | $2.15 |
| 52 Week High | $9.39 | $5.05 |
| Indicator | RVSN | BLRX |
|---|---|---|
| Relative Strength Index (RSI) | 29.87 | 54.84 |
| Support Level | $4.20 | $3.07 |
| Resistance Level | $5.21 | $3.53 |
| Average True Range (ATR) | 0.33 | 0.22 |
| MACD | 0.07 | -0.03 |
| Stochastic Oscillator | 14.28 | 54.10 |
Rail Vision Ltd is an early commercialization stage technology company focused on railway safety systems using AI-integrated sensing systems. The company develops and commercializes proprietary, multi-spectral electro-optic platforms that provide extended-range situational awareness and real-time hazard detection. Using machine learning algorithms to identify and classify obstacles, the company's technology enhances safety, improves operational efficiency, and supports continuity across deployments.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.